Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 1 5Phase 1/2 2Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Carcinoma, Hepatocellular 4Rectal Neoplasms 2Stomach Neoplasms 1Peripheral Nervous System Diseases 1Neoplasm Metastasis 1Liver Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × Folfox protocol × Clear all
NCT03031444 2021-02-01

PARECEC

Peking University Cancer Hospital & Institute

Phase 2/3 Completed
135 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡